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An infectious molecular clone was derived from the HIV-2UC2 isolate that previously was found to persistently infect and
induce an AIDS-like disease syndrome in baboons. The molecularly cloned virus (HIV-2UC2mc) showed in vitro properties
similar to those of the parental isolate with regard to T-cell tropism, cytopathicity, and the ability to infect primary baboon
PBMC. Nevertheless, when inoculated into two baboons, the cloned virus showed a limited ability to replicate in these
animals. DNA sequence analysis revealed a defective vpr gene in the UC2mc as well as in the pathogenic parental UC2
strain. Thus, the vpr gene is not required for the induction of disease in baboons. The attenuated infectious molecular clone
of UC2 should be useful for future studies designed to map the genetic determinants of HIV-2 pathogenesis in the baboon
model and to evaluate vaccine strategies. q 1996 Academic Press, Inc.
Two distinct types of the human immunodeficiency vi- In this report, the biologic and molecular characteris-
tics of an infectious molecular clone of the UC2 strainrus (HIV), the etiologic agent of AIDS, have been de-
scribed: HIV-1 and HIV-2 (1). Although these two HIV are presented. A biologic clone of the UC2 virus was first
derived by two serial endpoint dilutions of the human-types share similar genetic organization, biologic proper-
ties, and clinical manifestations in infected individuals, PBMC grown virus stock used to inoculate the baboons
in our previous studies (18). The UC2 biologic clone wasthere are noteworthy differences between them. Most
striking is the observation that HIV-2 strains share generated using human PBMC; nevertheless, the UC2
strain was originally recovered using the CEM T-cell linegreater serocrossreactivity and genetic identity with SIV
strains recovered from sooty mangabeys in West Africa (15). The host cell tropism of the UC2 biologic clone
(including it’s ability to grow in baboon PBMC) was exten-(SIVsm) and captive macaques (SIVmac) than they do
with HIV-1 isolates (2 – 5). Furthermore, in contrast to the sively characterized and was found to be similar to that
of the parental UC2 strain.worldwide pandemic of HIV-1 subtypes, HIV-2 infections
A full-length HIV-2UC2 molecular clone (herein referredappear to be concentrated mostly in West Africa (6, 7).
to as UC2mc) was obtained by cloning EcoRI-digestedNevertheless, cases of HIV-2 infection have been re-
DNA from human PBMC infected with the UC2 biologicported in the United States (8, 9) and an increased inci-
clone in a lambda vector as previously described (12).dence of infection with this virus type has been recently
Approximately 2 million plaques were screened and 3observed in Brazil and India (10, 11).
positive plaques were obtained following successiveWe have previously isolated and characterized several
rounds of plaque purification and hybridization. Of theseHIV-2 strains recovered from AIDS patients from the Ivory
3 positive clones, only one was found to contain full-Coast (12 – 16) and, more recently, from The Gambia
length HIV-2 proviral DNA. Human rhabdosarcoma (RD)(S. W. Barnett, unpublished). One of these strains, HIV-
cells were transfected with the cloned DNA and infec-2UC2 (herein called UC2), was first described because it
tious virus was recovered following cocultivation of thewas recovered from a patient with tuberculosis, high fe-
transfected cells with phytohemagglutinin (PHA)-stimu-ver, and chronic diarrhea, from Abidjan, Ivory Coast, who
lated purified peripheral blood mononuclear cellswas dually infected with HIV-2 and HIV-1 strains (15).
(PBMC) from seronegative human donors.The HIV-2UC2 isolate was later found to induce persistent
The entire UC2mc genome was subjected to DNAinfection and in some cases, an AIDS-like disease in
sequence analysis to determine its genetic structurebaboons (Papio cynocephalus) (17, 18).
and the relatedness of its deduced protein structure to
other known HIV strains. The proviral DNA sequence1 To whom correspondence and reprint requests should be ad-
dressed. of UC2mc was found to be 10,312 bp in length and its
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FIG. 1. Phylogenetic analysis of HIV-2 and SIV Gag (A) and Env (B) proteins. HIV-2 genetic subtypes (A – E) are designated at the right of
appropriate branches. To derive these trees, the Gag and Env protein coding regions of UC2mc were aligned with other HIV-2 sequences
using the Multiple Alignment Sequence Editor (MASE) (29). All columns containing gaps were removed prior to phylogenetic analysis.
Unweighted parsimony trees were created using Phylogenetic Analysis Using Parsimony (PAUP, version 3.1.1) (30). The estimated frequencies
of base substitutions in the unweighted trees were calculated using MacClade (31) and these values were used to create a weight matrix
that was used with PAUP to produce weighted parsimony trees. The Gag tree was based on 366 and the Env tree, 1254 varied nucleotide
sites. The DNA sequence of UC2mc was determined by the dideoxy chain termination method (32) employing standard kits (United States
Biochemical, Cleveland, OH) and by automated sequence analysis (Applied Biosystems Inc., Foster City, CA) as performed by the Chiron
DNA sequencing facility (Chiron Corp., Emeryville, CA). The entire UC2mc proviral DNA sequence can be found in the Los Alamos and
GenBank databases.
overall genetic structure was similar to those of other HIV-2BEN in the env gene and HIV-2GH1 and HIV-2FA in
gag. HIV-2D194 was isolated from a Gambian present-sequenced HIV-2 strains (4). Immunoblot analysis of
virus lysates prepared from UC2 has shown that, in ing exclusively with neurologic disease symptoms
(20). HIV-2BEN was recovered from a German AIDS pa-contrast to other HIV-2 strains such as HIV-2UC1 (14)
and HIV-2ST (19), the Env transmembrane glycoprotein tient with neurologic symptoms who was probably in-
fected in Mali; like UC2, this virus can infect nonhumanof UC2 does not become truncated following passage
through T-cell lines (S. W. Barnett, unpublished obser- primates (21). HIV-2GH1 was recovered from a Ghana-
ian prostitute with AIDS who worked in Abidjan, Ivoryvations). Accordingly, the molecularly cloned UC2 virus
encoded a full-length Env gp41. Coast (22), also the city of origin for the patient in-
fected with UC2 (15). Fasta analysis (23) of the UC2mcPhylogenetic analysis of UC2mc based on the nu-
cleotide variation in both the gag and env genes LTR and the deduced amino acids sequences of its
proteins also revealed that UC2mc shared the greatestclearly identified UC2mc as a member of the A subtype
of HIV-2 strains (Fig. 1). These viruses are more distant overall sequence identity with HIV-2D194 (Table 1).
Examination of the nucleotide sequence of UC2mcfrom SIV strains from macaques and sooty mangabeys
than are HIV-2 strains of subtype B. UC2mc showed also indicated that this virus possesses a defective
gene encoding the Vpr protein. When aligned with thethe closest phylogenetic relatedness to HIV-2D194 and
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TABLE 1
Relatedness of UC2mc to Other HIV and SIV Strains
Virus Strain gag pol gp120 gp41 vif vpx tat rev nef LTRa
HIV-2D194 94.4b 94.3 83.8 91.7 93.0 92.0 78.5 79.6 85.6 93.1
HIV-2BEN 93.5 94.2 78.0 89.4 92.6 85.0 78.5 80.6 82.5 94.7
HIV-2ST 90.6 88.8 80.5 80.2 87.9 90.2 67.7 72.2 72.7 85.2
HIV-2ROD 90.0 90.7 77.7 82.5 83.7 86.6 72.3 74.7 72.7 93.2
HIV-2GH1 92.9 94.5 78.5 90.8 92.6 93.8 77.7 81.6 84.8 90.9
HIV-2UC1 81.0 79.8 69.7 68.6 66.2 82.6 60.0 55.6 66.7 79.2
SIVSMMH4 87.2 86.7 69.5 70.8 68.8 80.2 49.6 63.7 64.4 79.5
SIVMAC239 84.5 82.0 71.8 70.0 71.6 84.7 56.9 61.7 52.7 68.1
HIV-1SF2 57.1 57.7 33.8 39.3 34.9 NA 42.9 34.7 50.7 59.3
Note. Sequence data for strains other than UC2mc were retrieved from Genbank and Human Retroviruses and AIDS (Los Alamos, NM) databases.
No analysis was performed for UC2mc Vpr because the coding region was interrupted by a large deletion.
a For LTR, values represent percentages of nucleotide sequence identity.
b Percentages of amino acid identities were determined using the FASTA program (23).
DNA sequence from the closely related HIV-2D194 as previously described (12). Approximately 10,000 tissue
culture infectious dose50 (TCID50) of this UC2mc stockstrain, two large deleted segments in the 5* region of
the UC2mc vpr gene were detected as well as a C to was used to infect various T-cell lines. Similar to the
parental UC2 isolate, UC2mc replicated efficiently in theT mutation further downstream. These changes would
result in premature terminations and extensive frame HUT78, MT-2, CEM, and Jurkat cell lines showing
50,000 cpm of reverse transcriptase (RT) activity pershifting in the deduced amino acid sequence of the
Vpr protein. DNA sequences also were obtained from milliliter of culture fluids (27) (data not shown). Syncytium
formation, balloon formation, and cell death were alsodirect sequencing of PCR-amplified cDNAs prepared
from viruses recovered from five UC2-infected ba- observed in these cells as well as in human PBMC in-
fected with either UC2mc and UC2.boons (Fig. 2) (18). Similar vpr coding sequence de-
fects were found in both the original UC2 inoculum When the UC2mc stock was used to infect PHA-
stimulated PBMC from seven different baboons, inand in all cultured viruses recovered from baboons
infected with this stock whether initially or after serial most cases, kinetics of replication similar to the paren-
tal UC2 strain were observed. However, peak RT levelspassage in vivo. The apparent absence of an intact
vpr gene in the parental UC2 inoculum as well as were reduced 3- to 15-fold as compared to results with
the UC2 parental isolate in five of seven of the animals’in the predominant viral species recovered after UC2
passage in several baboons (including two animals PBMC. Based on these findings, approximately 10,000
TCID50 of the UC2mc stock was then used to inoculatethat showed pathogenic symptoms) indicates that the
Vpr protein is not essential for persistent infection or two baboons whose PBMC supported UC2mc replica-
tion in vitro. These animals showed only transient repli-the induction of disease in baboons by HIV-2.
Similarly, previous studies with SIVmac239 in Rhe- cation of UC2mc in vivo as reflected in the ability to
recover virus from their PBMC only at 2 and 4 weekssus macaques showed that although the presence of
SIV vpr may provide a growth advantage for the virus postinoculation. Moreover, these animals did not sero-
convert as determined by an HIV-1/HIV-2 ELISAin vivo, progression to AIDS in this animal model can
occur without this gene (24, 25). Thus, if a viral species (Coulter, Hialeah, FL). In contrast, the UC2 parental
strain has repeatedly shown persistent infection and,with an intact vpr gene had been present in the original
UC2 inoculum, one would expect that this subspecies in some cases, pathogenesis in baboons (18, 28).
This report presents the derivation and characteriza-would have been selected for by passage in the ani-
mals, but this was not the case (Fig. 2) (26). The exten- tion of an infectious molecular clone of UC2, an HIV-2
strain that persistently infects and can induce an AIDS-sive deletions seen in the UC2 vpr gene most likely
account for the failure of this gene to be restored dur- like disease in baboons (18). Its genome places UC2
as a member of the A subtype of HIV-2. While theing in vivo infection of baboons as has been previously
observed when SIVmac239 with a mutated vpr was molecular clone resembled the parental virus in its in
vitro host cell tropism and cytopathic properties, it waspassaged in macaques (26).
A high titer virus stock of the infectious molecular only able to replicate for a short period of time in the
two baboons in which it was tested. This seeminglyclone of UC2 was prepared and titered in human PBMC
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FIG. 2. DNA sequence alignment showing deletions in vpr genes of UC2mc, UC2, and UC2-derived viruses recovered from infected baboons.
DNA sequences from the 5* end of vpr were aligned with the same region of the intact vpr gene from the HIV-2d194 strain employing Higgins
Automatic Multiple Sequence Alignment in the MacDNASIS program (Hitachi Software, San Bruno, CA). For all virus isolates except UC2mc, DNA
sequencing was performed following PCR amplification of cDNA prepared from viral RNA in culture supernatants. Baboon No. 9429 was persistently
infected with UC2 and died of an AIDS-like illness (18). Baboon No. 9206 was also persistently infected with UC2 and showed AIDS-like symptoms.
Baboons 6887, 238, and 114 received serially passaged UC2 from No. 9429. Virus isolates were recovered from the PBMC of infected baboons
following coculture with human PBMC from uninfected donors. Viral culture supernatants were lysed in RNAzol (Tel-Test, Friendswood, TX) and
cDNA was prepared by standard methods. The vpr regions of the UC2-derived virus isolates were subsequently PCR-amplified with primer sequences
from UC2mc, UC2VPR5* (5* AAGAAAGGGTGCACTTGCCTGGG 3*) and UC2VPR3* (5* GAGCTCTCTGGCGCCTTCAAGGG 3*) and sequenced by Taq
polymerase extension (fmole DNA Sequencing System, Promega) using the same primers.
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